RecruitingObesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Eligible age
18–99 yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Sponsor: Amgen
You may qualify if…
- ✓ Body Mass Index (BMI) ≥ 25 at screening.
- ✓ Weight loss of ≥ 10% on weekly GLP-1 RA.
- ✓ Stable body weight.
- ✓ Stable dose of GLP-1RA.
- ✓ Stable gastrointestinal (GI) tolerability.
- ✓ Contraception for females.
- ✓ Willingness to follow trial procedures for the duration of the trial.
You may not qualify if…
- ✕ Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
- ✕ Previous or planned surgical, endoscopic or device-based treatment for obesity.
- ✕ History of malignancy.
- ✕ Type 1/Type 2 diabetes mellitus (DM).
- ✕ Family or personal history of medullary thyroid cancer.
- ✕ Previous participation in a Maridebart Cafraglutide trial.
Where it's recruiting
Alabama
Pelham
Arizona
Chandler · Sun City
California
Palm Springs · Rialto · Rolling Hills Estates · San Diego …
Florida
Hialeah · Margate · Miami · Orlando …
Georgia
Johns Creek · Union City · Woodstock
Idaho
Meridian
Illinois
Skokie
Michigan
Troy
Mississippi
Ridgeland
Nevada
Las Vegas
New York
Rochester
North Carolina
Morehead City · Raleigh · Wilmington
Source: ClinicalTrials.gov · NCT07575399 · last updated 2026-06-11